BSX Stock Recent News
BSX LATEST HEADLINES
Boston Scientific announces favorable study data for its FARAPULSE PFA system and WATCHMAN FLX device at the AF Symposium 2025.
Boston Scientific (BSX) closed the most recent trading day at $98.66, moving +0.5% from the previous trading session.
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and efficacy outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure Device post cardiac ablation in both concomitant and sequential procedures MARLBOROUGH, Mass. , Jan. 16, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSE™ Pulsed Field Ablation (PFA) System* and the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device, respectively, during a late-breaking science session at AF Symposium 2025.
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
Boston Scientific's recent acquisitions have added numerous products with immense potential.
Boston Scientific Corporation (BSX) shares rise on acquisitions – earnings due in early February.
The latest trading day saw Boston Scientific (BSX) settling at $94.61, representing a -0.28% change from its previous close.
The Investment Committee discuss some stocks on the move today.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Boston Scientific inks a new agreement to acquire Bolt Medical, developer of Bolt IVL, for approximately $443 million.